Find out more about our clinical trials: Read More

Transforming the Future of Immunotherapy

Leadership

Founder, Chief Science Officer, Director

Theresa A. Deisher, Ph.D.

Theresa Deisher | LinkedIn
Doctoral degree in Molecular and Cellular Physiology from Stanford University School of Medicine. Holds more than 47 issued US/EU/Japan patents and 4 discoveries in clinical trials. Over 30 years of pharmaceutical leadership experience including Genentech, Repligen, ZymoGenetics, Immunex, and Amgen.

Chief Executive Officer

Joe Luminiello

Joe Luminiello | LinkedIn
Joe Luminiello is a healthcare industry executive with more than 30 years of commercial, development and C-suite-level experience including the launch of several successful drugs. He also has vast experience in the startup, merger and product-launch market segments including having held two previous CEO positions.  

CHIEF COMMERCIAL OFFICER

Brian Andersen, CCO

Brian Andersen | LinkedIn
Brian Andersen has 20 years experience as a corporate executive in the pharmaceutical and biotech industries including leading development efforts in start-up companies, launching new products, building specialty pharmacy distribution networks, as well as generating and executing marketing plans. He received his BSc in Biology from the University of Illinois and MBA from Northwestern University.  

CHIEF FINANCIAL OFFICER

Pearl Chan, CFO

Pearl Chan | LinkedIn
Pearl Chan has 25 years financial leadership experience in the tech industry, having built high-performing teams as CFO at PicMonkey, NetMotion Software and elsewhere, setting direction, executing key initiatives and catalyzing change. She has extensive experience preparing companies for significant capital and exit events. Pearl holds a BA from the University of Washington.  

Chief Medical Officer - Compassionate Use Program

Edward Loniewski, D.O.

Edward Loniewski | LinkedIn
Michigan State University, College of Osteopathic Medicine. University of Chicago Fellowship Arthritis & Adult Reconstruction. Founder Cellular Healing.

VP of Investor Relations

Terry Kopp

Terrence (Terry) Kopp had a successful 27-year history in marketing and sales with a major programming network in cable TV and has served in investor relations leadership for AVM Biotechnology since 2014, including leading series B, C, and D raises.

Director of Lab Research

Peter Jarzyna, Ph.D.

Peter Jarzyna | LinkedIn
Dr. Jarzyna received his Ph.D. in Pharmacy (tumor biology/imaging) from the University of Regensburg in Germany. While doing postdoctoral work at Mount Sinai Hospital in New York City, NY and later at Harvard Medical School in Boston, MA, he gained international experience in the field of preclinical cancer/imaging research and has successfully led many projects.

Director of Communications & Business Development

Jena Dalpez

Jena Dalpez | LinkedIn

Ms. Dalpez has an extensive background in communications, sales, marketing, contract management & negotiation, event planning, financial management, project & product management, and community outreach in the health insurance field as well as in the nonprofit sector.

Advisory Board

Scientific & Clinical Advisor

William Matsui, M.D.

William Matsui | LinkedIn
Deputy Director Livestrong Cancer Institutes, Professor Department of Oncology, Dell Medical School, received his AB in Biochemistry from Harvard and M.D. from the University of California SanFrancisco. Dr. Matsui has carried out research throughout his career making several key discoveries in clinical oncology.

Scientific & Clinical Advisor

Frank Buttgereit, M.D.

Frank Buttgereit | LinkedIn
Senior Consultant and Deputy Director, Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin. Professor of Rheumatology, Charité Universitätsmedizin Berlin. 

Scientific & Clinical Advisor

Gordon Roble, D.V.M.

Gordon Roble | LinkedIn
Dr. Roble is Director of Comparative Medicine at Fred Hutchinson Cancer Research Center. He received his MBA from NYU, his Doctor of Veterinary Medicine from Tufts University, and BA in Biology from Swarthmore College.

Scientific & Clinical Advisor

Gianpietro Dotti, M.D.

Director of the Immunotherapy Program at the University of North Carolina Lineberger Comprehensive Cancer Center and professor in the Department of Microbiology and Immunology at University of North Carolina at Chapel Hill. He received his medical degree from the University of Milan in Italy, with further training in hematology from the University of Parma and a post-doctoral fellowship from Baylor College of Medicine in Houston, Texas.

Scientific & Clinical Advisor

Gustavo Mahler, Ph.D.

Gustavo Mahler | LinkedIn
Former CEO AGC Biologics. Dr. Mahler received his Ph.D. in Biochemistry from the University of Buenos Aires, MBA from the University UNED of Madrid, and an Executive Certification in Management from MIT Sloan.

AVM Biotechnology’s Clinical Trial for Non-Hodgkin’s Lymphoma/Leukemia is Actively Enrolling